The Bio-Hacking Billionaires – The Economic Divide Between Those Who Can Afford to Live Forever and Those Who Can’t

Inside the rooms where the extremely wealthy discuss death, there’s a certain silence. Not the cozy quiet of a wellness retreat, but something more bizarre: the belief that a checkbook can solve the issue at hand. Bryan Johnson, the multimillionaire who created a personal laboratory out of his $800 million Braintree windfall, has come to represent that belief. It’s difficult to ignore the subtle calculation that goes into everything when you watch him pose with electrodes affixed to his temples and drink a measured slurry of supplements and olive oil. He’s not merely attempting to extend his life. His goal is to demonstrate that it is possible, ideally on camera.

When you sit with the numbers, they are challenging. Two million dollars annually. Over fifty pills every day. For cancer patients, let alone for vanity, the majority of national health systems cannot afford an MRI frequency. Johnson refers to his routine as the Blueprint Protocol, and its language—biomarkers, leaderboards, and optimization—has the polish of a startup pitch deck. However, the underlying idea predates Silicon Valley: mortality is a logistical issue that the wealthy will handle first, just like any other inconvenience.

Johnson’s actions might have some knock-on effects. Sleep monitoring has already done so. Continuous glucose monitoring, which was formerly a diabetic tool, is now a $300 toy for cryptocurrency traders and marathon runners. After following Johnson for a year, Chris Smith, a Netflix director, developed three modest habits: a sleep-tracking ring, earlier bedtimes, and less drinking. That’s the hopeful interpretation. Most of us could benefit from the diluted form of immortality, which is simply better hygiene.

However, there is a gap beneath, and it is not getting smaller. The wealthiest and poorest counties in the US already have life expectancies that differ by about fifteen years. When gene-targeted infusions, customized senolytic treatments, and 24-hour metabolic monitoring are added, the disparity does not increase exponentially. By category, it expands. A venture capitalist in Atherton and a janitor in West Virginia are no longer aging in the same kind of healthcare system. They hardly ever have the same conversation.

There’s also a feeling that the longevity industry has picked up on the strategy used by Ozempic and IVF in the past: begin as a luxury, create cultural envy, and then develop into a tiered service where the less expensive version is real but subpar. The hyperbaric pod turns into a membership in yoga. Johnson, to his credit, has stopped the teenage-son blood plasma, which is now available at the grocery store as an over-the-counter NAD+ supplement. It’s a familiar shape. The cost isn’t.

Part of the unnerving appeal is that Johnson cheerfully embraces the label of “vampire tech bro” that critics have given him. He looks genuinely content. He and his documentarians are unable to determine whether that happiness is the result of reaching optimal magnesium levels or of finally discovering a project worth $200 million of obsession. The larger picture he sits inside is more obvious. There are currently about 700 longevity startups operating worldwide, the majority of which are concentrated in Singapore, Boston, and the Bay Area. Most of their investors are the same individuals they want to survive.

As this develops, it’s not really clear whether Johnson will live to be 140 years old. What the rest of us inherit when he passes away is the question.